Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results

Vural, Esra; Hazar, Leyla; SIRAKAYA, ENDER

doi:10.14744/eer.2022.22931

Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results

Esra VURAL, (Kayseri Şehir Hastanesi, Göz Hastalıkları Kliniği, Kayseri, Türkiye)

Leyla HAZAR, (Dicle Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Diyarbakır, Türkiye)

Ender SIRAKAYA (Kayseri Şehir Hastanesi, Göz Hastalıkları Kliniği, Kayseri, Türkiye)

European eye research

4 0

Yıl: 2022 Cilt: 2 Sayı: 2 Sayfa Aralığı: 69 - 74 Metin Dili: İngilizce DOI: 10.14744/eer.2022.22931 İndeks Tarihi: 05-05-2023

Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results

Öz:

Purpose: The purpose of the study was to compare the results of intravitreal bevacizumab in patients with macular edema (ME) due to branch retinal vein occlusion (BRVO) according to different ME morphologies. Methods: In this retrospective study, 24, 13, and 22 patients with ME type due BRVO were included in the serous retinal detachment group, cystoid ME group, and diffuse ME group, respectively. The best-corrected visual acuity (BCVA) was evaluated with an ETDRS chart, and central macular thickness (CMT) was evaluated by spectral domain optical coherence tomography at the 1st, 2nd, and 3rd months. Results: The mean ages of the patients were 64.25±7.80, 64.84±7.96, and 61.81±6.67 years in the serous, cystoid, and diffuse groups, respectively (p=0.414). While no significant difference was observed in the serous group in terms of BCVA and CMT at the 1st month after injection compared with that in the cystoid group (p=0.201 and p=0.986), BCVA and CMT values at the 2nd and 3rd months were statistically different (p=0.021, p=0.003, p=0.015, and p=0.006, respectively). When the serous group and the diffuse group were compared, only a significant difference was found in CMT at the 2nd month (p=0.016). Conclusion: Intravitreal bevacizumab treatment was more effective in terms of anatomical and visual results in the serous group compared with that in the cystoid group; however, at the end of the 3rd month, it showed similar results with the diffuse group.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Kanra AY, Akçakaya AA, Yaylalı SR, Altınel MG, Sevimli N. The efficacy and safety of ıntravitreal dexamethasone ımplant for the treatment of macular edema related to retinal vein occlusion: Real-life data and prognostic factors in a Turkish population. Turk J Ophthalmol 2017;47:331–7.
2. Acar N. Retina ven-dal tıkanıklığı ve hemisferik tıkanma. Turk Klinikleri J Ophthalmol Spec Top 2011;4:40–50.
3. Spaide RF. retınal vascular cystoıd macular edema: Review and new theory. Retina 2016;36:1823–42.
4. Bike Hİ, Sever Ö, Horozoğlu F. Retinal ven tıkanıklığı tedavisinde intravitreal deksametazon implant ile ranibizumab: Altı aylık sonuçlar. MN Oftalmol 2018;25:152.
5. Keane PA, Sadda SR. Predicting visual outcomes for macular disease using optical coherence tomography. Saudi J Ophthalmol 2011;25:145–58.
6. Ota T, Tsujikawa A, Murakami T, Ogino K, Muraoka Y, Kumagai K, et al. Subfoveal serous retinal detachment associated with extramacular branch retinal vein occlusion. Clin Ophthalmol 2013;7:237–41.
7. Dysli M, Rückert R, Munk MR. Differentiation of underlying pathologies of macular edema using spectral domain optical coherence tomography (SD-OCT). Ocul Immunol Inflamm 2019;27:474–83.
8. Dogan E, Sever O, Çakır BK, Celik E. Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion. Clin Ophthalmol 2018;12:1465–70.
9. Koki G, Aboubakar H, Nyamsi PB, Teperesna P, Nomo A, Epée E, et al. Retinal vein occlusions treated by intravitreal bevacizumab injections at the hospital of ınstruction, application and reference of the Armed forces of Yaoundé. J Fr Ophtalmol 2020;43:51–8.
10. Gallego-Pinazo R, Dolz-Marco R, Pardo-López D, Martínez- Castillo S, Lleó-Pérez A, Arévalo JF, et al. Ranibizumab for serous macular detachment in branch retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol 2013;251:9–14.
11. Coscas F, Glacet-Bernard A, Miere A, Caillaux V, Uzzan J, Lupidi M, et al. Optical coherence tomography angiography in retinal vein occlusion: Evaluation of superficial and deep capillary plexa. Am J Ophthalmol 2016;161:160–71.
12. Celık E, Doğan E, Turkoglu EB, Çakır B, Alagoz G. Serous retinal detachment in patients with macular edema secondary to branch retinal vein occlusion. Arq Bras Ophthalmol 2016;79:9– 11.
13. Park SP, Ahn JK, Mun GH. Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion. Retina 2010;30:281–6.
14. Noma H, Funatsu H, Mimura T, Tatsugawa M, Shimada K, Eguchi S. Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion. Retina 2012;32:86–91.
15. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041–9.
16. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298–306.
17. Pearce I, Clemens A, Brent MH, Lu L, Gallego-Pinazo R, Minnella AM, et al. Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study. PLoS One 2020;15:e0234739.
18. Cinal A, Ziemssen F, Bartz-Schmidt KU, Gelisken F. Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2011;249:513–20.
19. Elbay A, Ozdemir H, Koytak A, Melikov A. Intravitreal dexamethasone ımplant for treatment of serous macular detachment in central retinal vein occlusion. J Ocul Pharmacol Ther 2017;33:473–9.
20. Sekiryu T, Iida T, Sakai E, Maruko I, Ojima A, Sugano Y, et al. Fundus autofluorescence and optical coherence tomography findings in branch retinal vein occlusion. J Ophthalmol 2012;2012:1–8.
21. Pfister M, Rothweiler F, Michaelis M, Cinatl J Jr., Schubert R, Koch FH, et al. Correlation of inflammatory and proangiogenic cytokines from undiluted vitreous samples with spectral domain OCT scans, in untreated branch retinal vein occlusion. Clin Ophthalmol 2013;7:1061–7.
22. Choi KE, Yun C, Cha J, Kim SW. OCT angiography features associated with macular edema recurrence after intravitreal bevacizumab treatment in branch retinal vein occlusion. Sci Rep 2019;9:14153.
23. Coughlin BA, Feenstra DJ, Mohr S. Müller cells and diabetic retinopathy. Vis Res 2017;139:93–100.
24. Murakami T, Nishijima K, Sakamoto A, Ota M, Horii T, Yoshimura N. Foveal cystoid spaces are associated with enlarged foveal avascular zone and microaneurysms in diabetic macular edema. Ophthalmology 2011;118:359–67.

APA	Vural E, Hazar L, SIRAKAYA E (2022). Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. , 69 - 74. 10.14744/eer.2022.22931
Chicago	Vural Esra,Hazar Leyla,SIRAKAYA ENDER Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. (2022): 69 - 74. 10.14744/eer.2022.22931
MLA	Vural Esra,Hazar Leyla,SIRAKAYA ENDER Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. , 2022, ss.69 - 74. 10.14744/eer.2022.22931
AMA	Vural E,Hazar L,SIRAKAYA E Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. . 2022; 69 - 74. 10.14744/eer.2022.22931
Vancouver	Vural E,Hazar L,SIRAKAYA E Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. . 2022; 69 - 74. 10.14744/eer.2022.22931
IEEE	Vural E,Hazar L,SIRAKAYA E "Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results." , ss.69 - 74, 2022. 10.14744/eer.2022.22931
ISNAD	Vural, Esra vd. "Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results". (2022), 69-74. https://doi.org/10.14744/eer.2022.22931

APA	Vural E, Hazar L, SIRAKAYA E (2022). Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. European eye research, 2(2), 69 - 74. 10.14744/eer.2022.22931
Chicago	Vural Esra,Hazar Leyla,SIRAKAYA ENDER Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. European eye research 2, no.2 (2022): 69 - 74. 10.14744/eer.2022.22931
MLA	Vural Esra,Hazar Leyla,SIRAKAYA ENDER Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. European eye research, vol.2, no.2, 2022, ss.69 - 74. 10.14744/eer.2022.22931
AMA	Vural E,Hazar L,SIRAKAYA E Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. European eye research. 2022; 2(2): 69 - 74. 10.14744/eer.2022.22931
Vancouver	Vural E,Hazar L,SIRAKAYA E Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results. European eye research. 2022; 2(2): 69 - 74. 10.14744/eer.2022.22931
IEEE	Vural E,Hazar L,SIRAKAYA E "Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results." European eye research, 2, ss.69 - 74, 2022. 10.14744/eer.2022.22931
ISNAD	Vural, Esra vd. "Comparison of intravitreal bevacizumab responses in different morphologies of macular edema due to branch retinal vein occlusion: Short-term results". European eye research 2/2 (2022), 69-74. https://doi.org/10.14744/eer.2022.22931